New drug plozasiran aims to lower high fats in the blood
NCT ID NCT04998201
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2b trial tested plozasiran, an experimental drug, in 353 adults with mixed dyslipidemia (high triglycerides and cholesterol). Participants received either plozasiran or a placebo, and researchers measured changes in blood fat levels over 48 weeks. The goal is to see if the drug can safely lower these fats when added to standard diet and statin therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plozasiran (ARO-APOC3 injection)
What this could lead to
If successful, plozasiran could offer a new option to help control high triglycerides and cholesterol in people with mixed dyslipidemia.
What could go wrong
This is a mid-stage trial with results not yet published. The drug may not prove effective or safe enough for approval, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Fort Lauderdale, Florida, 33308, United States
-
Research Site 10
Montreal, Quebec, H2W2T2, Canada
-
Research Site 11
Auckland, 2025, New Zealand
-
Research Site 12
Dayton, Ohio, 45419, United States
-
Research Site 13
San Antonio, Texas, 78249, United States
-
Research Site 14
Miami Springs, Florida, 33166, United States
-
Research Site 15
Concord, Ontario, L4K 4M2, Canada
-
Research Site 16
Christchurch, 8013, New Zealand
-
Research Site 17
New Windsor, New York, 12553, United States
-
Research Site 18
Dunwoody, Georgia, 30338, United States
-
Research Site 19
Clayton, Victoria, 3168, Australia
-
Research Site 2
Boca Raton, Florida, 33434, United States
-
Research Site 20
Balatonfüred, H-8230, Hungary
-
Research Site 21
Debrecen, H-4032, Hungary
-
Research Site 22
Nyíregyháza, H-4405, Hungary
-
Research Site 24
Lodz, 94-048, Poland
-
Research Site 25
Poznan, 61-655, Poland
-
Research Site 26
Rzeszów, 35-055, Poland
-
Research Site 27
Joondalup, Western Australia, 6027, Australia
-
Research Site 28
Lodz, 93-338, Poland
-
Research Site 29
Adelaide, South Australia, 5000, Australia
-
Research Site 3
Beverly Hills, California, 90211, United States
-
Research Site 30
Morayfield, Queensland, 4506, Australia
-
Research Site 31
Las Vegas, Nevada, 89121, United States
-
Research Site 32
Houston, Texas, 77030, United States
-
Research Site 4
Franklin, Ohio, 45005, United States
-
Research Site 5
Pembroke Pines, Florida, 33024, United States
-
Research Site 6
Houston, Texas, 77002, United States
-
Research Site 7
Greenville, South Carolina, 29607, United States
-
Research Site 8
Northridge, California, 91325, United States